Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Biogen Idec and Isis Pharmaceuticals form collaboration for neurological disorders

Sep. 12, 2013

Neurocrine discloses results from phase IIb trial of NBI-98854 for treatment of tardive dyskinesia

Sep. 10, 2013

Spanish team prepares novel sigma1 receptor ligands

Sep. 10, 2013

Neuren Pharmaceuticals cleared to conduct phase II NNZ-2566 trial

Sep. 10, 2013

Lilly presents new mGlu2 positive allosteric modulator for the treatment of anxiety

Sep. 10, 2013

Civitas Therapeutics begins phase IIb study of inhaled levodopa

Sep. 9, 2013

QRxPharma to discuss MoxDuo NDA with FDA prior to refiling

Sep. 9, 2013

Exon-skipping compound PRO-053 begins phase I/II trial for Duchenne muscular dystrophy

Sep. 9, 2013

CP-9531 demonstrates efficacy for multiple sclerosis

Sep. 9, 2013

Reductions in rheumatic pain seen with willow bark extract STW-33-1

Sep. 9, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...